{"schema":"sb.node.v1","id":"sb:e/6d911ae375a0bffac4f2f4c7","kind":"entity","label":{"text":"glp-1","locale":"en"},"identity":{"anchor":"label:en:glp-1","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T19:01:28.512480+00:00","snapshot":"deploy 70ebd9dbd4d5310a3fc4fbf26ebf9339092fb86c"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":318,"separatePublishers":95,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-06","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.22: about 78% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto"],"activeDays":42,"assertions":{"regulatory-approval":26,"utterance":9,"launch-release":8,"acquisition":7,"price-threshold":6,"meeting-visit":4}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":8,"byKind":{"observation":8},"withheld":{"state":"withheld","count":4,"reason":"4 receipts withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/55aaa64ee3720411c603fb80","kind":"observation","label":"Medical Xpress · 2026-10-07 · Pilot trial suggests structured support may help limit weight regain after GLP-1 treatment","url":"https://medicalxpress.com/news/2026-10-trial-limit-weight-regain-glp.html"},{"id":"sb:o/5b1b1f6a23cee364bb8657dc","kind":"observation","label":"Fierce Pharma · 2026-10-07 · Noom puts a spooky voice to the haunting threat of weight regain for GLP-1 users in new spot","url":"https://www.fiercepharma.com/marketing/noom-puts-spooky-voice-haunting-threat-weight-regain-glp-1-users-new-spot"},{"id":"sb:o/b0fa47e5aa342cf81ebbe735","kind":"observation","label":"Health Policy Watch · 2026-10-07 · GLP-1 Drugs? Surgery? WHO Issues Guidelines for Obesity in Children","url":"https://healthpolicy-watch.news/glp-1-drugs-surgery-who-issues-guidelines-for-obesity-in-children/"},{"id":"sb:o/b28ef0a29cb788814e4772d7","kind":"observation","label":"PR Newswire · 2026-10-07 · FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body","url":"https://www.prnewswire.com/news-releases/fibrobiologics-files-patent-application-for-technology-designed-to-produce-glp-1-and-other-therapeutic-peptides-inside-the-body-302901121.html"},{"id":"sb:o/b04b358a5fcb3723633b9eda","kind":"observation","label":"Nutraceutical Business Review · 2026-10-07 · Carob extract boosts GLP-1 and CCK in new studies","url":"https://nutraceuticalbusinessreview.com/carob-extract-boosts-glp-1-cck-studies"},{"id":"sb:o/848e1bb624d0917e5e293689","kind":"observation","label":"Nutraceutical Business Review · 2026-10-06 · Phaseolean®: Carb control & satiety signalling to target body’s GLP-1, PYY & Ghrelin levels","url":"https://nutraceuticalbusinessreview.com/phaseolean-carb-control-satiety-signalling-to-target"},{"id":"sb:o/2a233848de528947f39114f6","kind":"observation","label":"Nutraceutical Business Review · 2026-10-06 · Lemme rebrands GLP-1 supplement after legal scrutiny","url":"https://nutraceuticalbusinessreview.com/lemme-rebrands-glp-1-supplement-after-legal-scrutiny"},{"id":"sb:o/51cb83d602a13f48b7b369d0","kind":"observation","label":"Retail Dive · 2026-10-06 · How GLP-1 users are forcing retailers to rethink everything","url":"https://www.retaildive.com/news/glp1-users-apparel-retailers-rethink-everything-returns-davids-bridal/831835/"}],"cursor":null,"order":"newest first; we keep the 8 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":12,"byKind":{"claim":2,"co-mentioned":10},"items":[{"id":"sb:p/99acd08f6bedb3453f2ab0f9","kind":"claim","label":"FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — corroborated","role":"named-in","relationKind":"claim","members":1},{"id":"sb:p/811cdf24f8dab4ba1680d563","kind":"claim","label":"WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight — corroborated","role":"named-in","relationKind":"claim","members":1},{"kind":"relation","label":"co-mentioned with eli lilly (89 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/780e192cbb11a0ba2d140505"},{"kind":"relation","label":"co-mentioned with fda (85 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/10257615bbfa78ed1d42ee2a"},{"kind":"relation","label":"co-mentioned with glp-1s (71 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b7bf40cafc38451ad9cfa045"},{"kind":"relation","label":"co-mentioned with ai (62 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/dcde6980fe390fd903a1cd36"},{"kind":"relation","label":"co-mentioned with novo nordisk (55 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1be62960e6ad4da2c2b9f6cf"},{"kind":"relation","label":"co-mentioned with mounjaro (51 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/73192c912bb21678c37bcbc7"},{"kind":"relation","label":"co-mentioned with zepbound (44 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a5b22a202d1fdb613ee2dd47"},{"kind":"relation","label":"co-mentioned with buy (37 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5731f09e6c2d2b276200929c"}],"cursor":"c1.eyJpZCI6InNiOmUvNmQ5MTFhZTM3NWEwYmZmYWM0ZjJmNGM3IiwibCI6InJlbGF0aW9ucyIsIm8iOjEwLCJrIjpudWxsLCJhIjoiMjAyNi0xMC0wOFQxOTowMToyOC41MTI0ODArMDA6MDAifQ","order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/6d911ae375a0bffac4f2f4c7","mcp":"traverse {\"id\":\"sb:e/6d911ae375a0bffac4f2f4c7\"}","page":"/entity/glp-1/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/6d911ae375a0bffac4f2f4c7\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/6d911ae375a0bffac4f2f4c7\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/6d911ae375a0bffac4f2f4c7\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/6d911ae375a0bffac4f2f4c7\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}